COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01757613
Recruitment Status : Completed
First Posted : December 31, 2012
Last Update Posted : May 14, 2014
CenTrial GmbH
d.s.h. statistical services GmbH
Information provided by (Responsible Party):
Dolorgiet GmbH & Co. KG

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014